A misdirected conundrum in translational HFpEF research

In 2021, the term “heart failure (HF) with preserved ejection fraction” (HFpEF) garnered more than 900 PubMed citations, which is greater than a 10-fold increase from 2011. Of these>900 peer-reviewed publications published in 2021, more than a third corresponded to commentaries, editorials, reviews, and systematic reviews in HFpEF, in contrast to less than 100 clinical HFpEF studies. Despite the exponential growth in publications, there has been little advances in therapies for HFpEF [1 –3], with only the first positive multinational clinical drug study reported in October 2021 [1].

Source: Journal of Molecular and Cellular Cardiology - April 8, 2022 Category: Cytology Authors: Mar ía Valero-Muñoz, Flora Sam Tags: Letter to the editor Source Type: research